rna
interfer
rnai
rapidli
becom
import
method
analyz
gene
function
mani
eukaryot
hold
promis
develop
therapeut
gene
silenc
induct
rnai
reli
small
silenc
rna
affect
specif
messeng
rna
mrna
degrad
two
type
small
rna
molecul
ie
small
interf
rna
sirna
microrna
mirna
central
rnai
drug
discoveri
studi
novel
treatment
sirna
current
target
wide
rang
diseas
includ
variou
viral
infect
cancer
lung
diseas
gener
attract
target
sirna
therapeut
lethal
preval
addit
lung
anatom
access
therapeut
agent
via
intrapulmonari
rout
recent
increas
evid
indic
mirna
play
import
role
lung
abnorm
inflamm
oncogenesi
therefor
mirna
target
therapeut
purpos
review
present
strategi
rnai
deliveri
discuss
current
stateoftheart
rnaibas
therapeut
variou
lung
diseas
tradit
surgeri
bivasbenita
et
al
report
mortal
occur
result
use
endotrach
techniqu
endotrach
applic
current
use
mani
practition
pulmonari
field
use
studi
pulmonari
drug
deliveri
mice
howev
approach
complex
human
artifici
path
deliveri
drug
lung
use
therefor
method
use
anim
model
test
evalu
reliabl
possibl
clinic
applic
intratrach
rout
anesthesia
trachea
expos
surgic
tube
needl
insert
incis
made
tracheal
ring
complic
vascular
injuri
air
leakag
possibl
due
tracheotomi
b
endotrach
rout
sirna
spray
directli
mouth
lung
use
microspray
aerol
penncenturi
philadelphia
pa
usa
laryngoscop
import
maintain
clear
view
trachea
procedur
intranas
deliveri
anoth
common
method
pulmonari
drug
applic
anim
studi
mani
studi
vivo
success
demonstr
deliv
sirna
lung
intranas
experiment
setup
intranas
deliveri
spray
droplet
simpl
painless
anim
although
success
deliv
sirna
intranas
rodent
complet
extrapol
human
use
signific
differ
lung
anatomi
approach
potenti
clinic
applic
sirna
phase
ii
clinic
trial
initi
treatment
respiratori
syncyti
viru
rsv
infect
make
use
intranas
applic
nake
chemic
modifi
sirna
molecul
target
viral
gene
product
see
section
detail
intranas
entri
long
use
administ
small
molecul
protein
system
deliveri
nasal
mucosa
highli
vascular
deliveri
thin
epithelium
medic
across
surfac
area
result
rapid
absorpt
medic
blood
therefor
sirna
administ
intranas
might
deposit
nose
may
unabl
reach
lower
respiratori
tract
fact
report
intranas
applic
unformul
sirna
result
lower
deliveri
effici
homogen
pulmonari
distribut
achiev
intratrach
applic
intranas
method
suitabl
lung
diseas
upper
respiratori
infect
rsv
also
potenti
system
deliveri
rather
pulmonari
deliveri
sirna
therefor
import
consid
rout
administr
anim
studi
assess
deliveri
therapeut
efficaci
formul
pulmonari
deliveri
care
choic
effici
deliveri
respons
condit
lung
diseas
necessari
use
aerosol
deliv
medic
lung
long
histori
administr
inhal
popular
noninvas
method
deliv
agent
lung
sever
inhal
devic
avail
deliveri
drug
lung
meter
dose
inhal
mdi
dri
powder
inhal
dpi
common
mode
inhal
deliveri
mdi
commonli
use
inhal
sever
lung
diseas
asthma
bronchiti
chronic
obstruct
pulmonari
diseas
copd
spacer
extern
devic
attach
mdi
allow
better
drug
deliveri
enhanc
actuat
inhal
coordin
mdi
propel
one
gase
call
chlorofluorocarbon
cfc
although
cfc
drug
safe
patient
inhal
harm
environ
therefor
develop
inhal
sirna
may
best
way
forward
dpi
devic
deliv
medic
lung
form
dri
powder
use
dpi
alreadi
shown
promis
vivo
deliveri
therapeut
macromolecul
insulin
lowmolecularweight
heparin
thu
could
better
devic
deliv
sirna
lung
advantag
dpi
improv
stabil
steril
biomolecul
liquid
aerosol
propellantfre
format
although
drug
commonli
deliv
lung
inhal
vivo
studi
use
sirna
reli
intratrach
intranas
deliveri
reason
could
difficulti
formul
inhal
sirna
maintain
stabil
deliveri
process
suitabl
carrier
also
need
protect
nucleic
acid
degrad
due
shear
forc
increas
temperatur
dri
process
use
spraydri
techniqu
engin
dri
powder
formul
sirna
nanoparticl
might
enabl
local
deliveri
biolog
activ
sirna
directli
lung
tissu
demonstr
futur
techniqu
desir
estim
vivo
studi
sirna
therapi
inhal
long
term
anticip
sophist
devic
clinic
use
current
develop
suitabl
two
main
barrier
effici
pulmonari
sirna
deliveri
cell
lung
first
complex
branch
anatomi
lung
biomechan
barrier
mucu
layer
cover
airway
cell
figur
remark
featur
respiratori
tract
high
degre
branch
airway
consist
respiratori
bronchiol
alveolar
duct
alveolar
sac
structur
bear
alveoli
tini
air
sac
ga
exchang
take
place
gener
acknowledg
critic
factor
effici
sirna
deliveri
depend
properti
rnai
drug
particl
term
size
charg
shape
veloc
densiti
effici
pulmonari
sirna
deliveri
particl
must
deposit
lower
respiratori
tract
deposit
airway
affect
particl
size
patient
pulmonari
function
particl
size
found
appropri
deposit
lower
respiratori
tract
addit
presenc
mucu
surfact
protein
mucociliari
clearanc
action
phagocytosi
macrophag
present
major
barrier
target
pulmonari
deliveri
therefor
deliveri
system
usual
requir
deliveri
vector
vector
need
design
order
maxim
sirna
deposit
diseas
area
respiratori
tract
besid
extracellular
barrier
sirna
deliveri
also
depend
physiolog
featur
respiratori
tract
may
chang
diseas
stage
characterist
patient
activ
stage
lung
diseas
physiolog
condit
airway
might
chang
signific
impact
effici
pulmonari
deliveri
system
infect
inflamm
allerg
reaction
increas
mucu
secret
along
impair
mucociliari
clearanc
moreov
asthma
copd
chronic
inflammatori
condit
lung
associ
structur
remodel
inappropri
mainten
normal
lung
function
airway
wall
thick
high
viscos
composit
mucu
layer
might
alter
patient
inflammatori
lung
diseas
figur
extracellular
barrier
pulmonari
sirna
deliveri
anatom
featur
respiratori
tract
high
degre
branch
mucu
line
respiratori
epithelium
nasal
caviti
termin
bronchiol
deposit
particl
ciliat
epitheli
cell
rapidli
clear
mucociliari
clearanc
action
mucu
mucociliari
clearanc
mucustrap
particl
pulmonari
defens
mechan
physiolog
barrier
alveolar
clara
cell
type
ii
alveolar
cell
secret
surfac
alveolar
epithelium
form
thin
layer
pulmonari
surfact
surfact
act
main
barrier
sirna
deliveri
reduc
transfect
effici
addit
macrophag
locat
alveoli
rapidli
engulf
foreign
particl
phagocytosi
particl
taken
macrophag
subsequ
degrad
insid
cell
factor
present
major
barrier
target
pulmonari
deliveri
second
airway
cell
membranc
intracellular
barrier
figur
effici
gene
silenc
lung
sirna
must
deliv
site
action
stabl
enter
target
cell
present
cytoplasm
suffici
concentr
sirna
reach
target
cell
must
traffick
cytoplasm
taken
argonaut
ago
silenc
complex
risc
degrad
mrna
subsequ
suppress
sequencespecif
gene
express
effici
endocytosi
occur
particl
nm
size
particl
within
size
rang
could
also
avoid
macrophag
uptak
delay
lung
clearanc
physicochem
properti
sirna
also
play
signific
role
cross
biolog
membran
despit
small
size
neg
charg
chemic
degrad
sirna
molecul
prevent
readili
cross
biolog
membran
therefor
effici
sirna
deliveri
approach
need
overcom
limit
facilit
cellular
uptak
one
main
function
deliveri
vector
facilit
cellular
uptak
sirna
electrostat
complex
sirna
molecul
cation
lipid
polym
help
mask
net
neg
charg
posit
charg
sirna
carrier
complex
interact
anion
proteoglycan
cell
membranc
form
endocyt
vesicl
enter
cell
endocytosi
cellular
intern
sirna
carrier
complex
endocyt
vesicl
transport
along
microtubul
lysosom
coloc
microtubuleorgan
center
avoid
lysosom
degrad
sirna
must
escap
endosom
cytoplasm
associ
rnai
machineri
endosom
escap
major
barrier
effici
sirna
deliveri
endosom
entrap
lysosom
degrad
sirna
carrier
contribut
low
transfect
effici
major
difficulti
deliveri
vector
ideal
deliveri
agent
protect
sirna
enzymat
degrad
facilit
cellular
uptak
promot
endosom
escap
insid
cell
neglig
toxic
multipl
approach
deliveri
sirna
report
rang
rel
simpl
direct
administr
salineformul
sirna
lipidbas
polymerbas
nanoparticl
approach
sirna
conjug
complex
approach
neg
charg
chemic
degrad
sirna
physiolog
relev
condit
make
deliveri
major
challeng
accordingli
deliveri
sirna
usual
requir
vector
carrier
transfect
target
cell
gener
viral
nonvir
vector
assess
sirna
deliveri
lung
cell
viral
vector
retrovirus
adenovirus
demonstr
mediat
gene
silenc
vitro
lung
model
induc
rnai
rang
anim
tissu
recent
guo
et
al
show
lentivirusmedi
sirna
use
specif
knock
express
nuclear
protein
vivo
result
inhibit
tumor
growth
howev
viralbas
deliveri
sever
disadvantag
immun
respons
virus
imped
gene
deliveri
also
potenti
caus
sever
complic
recent
welldocu
case
death
jess
gelsing
due
complic
relat
adenovir
deliveri
vector
highlight
problem
addit
viral
vector
may
insert
genom
random
posit
host
chromosom
eventu
restrict
gene
function
intracellular
barrier
pulmonari
sirna
deliveri
barrier
cellular
intern
depend
surfac
properti
sirna
carrier
eg
charg
size
sirna
success
taken
target
cell
endocytosi
main
barrier
deliv
sirna
site
action
endosom
entrap
lysosom
degrad
sirna
carrier
direct
targetgen
silenc
sirna
need
escap
endosom
cytoplasm
associ
silenc
complex
risc
direct
cleavag
mrna
bear
complementari
bind
site
altern
viral
vector
nonvir
vector
includ
lipid
polymerbas
vector
gener
use
deliveri
sirna
lung
due
reduc
toxic
ongo
research
transfect
primari
cell
whole
organ
sirna
use
nonvir
transfect
agent
produc
promis
result
lipidbas
deliveri
vector
success
use
deliv
sirna
vitro
vivo
cation
lipid
compos
posit
charg
head
linker
hydrophob
gener
lipidbas
complex
easi
formul
good
transfect
efficaci
achiev
due
interact
neg
charg
cell
membranc
mani
commerci
sirna
transfect
agent
lipidbas
deliveri
system
also
employ
pulmonari
deliverydharmfect
oligofectamin
lipofectamin
transittko
similarli
cation
polym
also
assess
sirna
deliveri
lung
cell
cation
polym
polyethylenimin
pei
wide
use
sirna
deliveri
pei
consid
gold
standard
vitro
gene
deliveri
transfect
effici
depend
molecular
weight
degre
branch
hand
lipidbas
vector
also
induc
toxic
nonspecif
activ
inflammatori
cytokin
interferon
respons
although
polymerbas
vector
elicit
rel
less
strong
immun
respons
lipidbas
vector
effect
sirna
deliveri
local
area
lung
diseas
requir
attent
develop
nontox
deliveri
vector
import
point
sirnamedi
inhibit
gene
express
whether
observ
effect
specif
rather
due
offtarget
effect
free
potenti
interferon
respons
interestingli
studi
shown
possibl
administ
nake
sirna
mice
downregul
endogen
exogen
target
without
induc
interferon
respons
term
nake
sirna
refer
deliveri
sirna
without
deliveri
vector
nake
sirna
degrad
serum
endonucleas
usual
remov
glomerular
filtrat
result
short
plasma
halflif
min
thu
studi
system
deliveri
nake
sirna
fail
achiev
downregul
target
gene
contrast
also
success
local
deliv
nake
sirna
lung
report
use
deliveri
vector
show
signific
differ
gene
silenc
effici
compar
nake
sirna
inde
one
clinic
trial
deliveri
nake
sirna
treatment
rsv
use
success
evid
nake
sirna
clinic
applic
highli
chemic
modifi
prevent
nucleaseinduc
degrad
presum
minim
immun
stimulatori
effect
although
unclear
nake
sirna
cross
cell
membran
gain
access
cytoplasm
remain
intact
perform
biolog
action
anim
human
trial
conduct
success
show
efficaci
nake
sirna
administ
intranas
explan
confirm
physiolog
damag
respiratori
epitheli
cell
caus
viral
infect
may
possibl
influenc
mysteri
activ
chang
airway
epitheli
cell
membranc
caus
infecti
diseas
might
affect
cellular
intern
nake
sirna
deliveri
advantag
simpl
format
absenc
toxic
inflammatori
respons
usual
associ
deliveri
vector
nevertheless
advantag
nake
sirna
deliveri
vector
treatment
lung
diseas
controversi
vivo
investig
nake
sirna
nonvir
vector
requir
lung
diseas
major
caus
death
diminish
qualiti
life
respons
suffer
mani
patient
variou
lung
diseas
make
life
extrem
difficult
patient
sever
case
lung
diseas
result
death
high
death
rate
associ
lung
cancer
partial
due
fact
unfortun
difficult
cure
copd
fourthlead
caus
death
industri
countri
predict
becom
third
therefor
decis
action
need
stem
rise
health
econom
burden
repres
chronic
lung
diseas
copd
asthma
disord
airway
larg
relat
presenc
persist
inflamm
approv
inhal
corticosteroid
pioneer
new
gener
therapi
treat
chronic
inflammatori
diseas
first
time
antiinflammatori
product
avail
reduc
characterist
lung
inflamm
airway
associ
obstruct
corticosteroid
still
import
therapeut
intervent
howev
use
limit
copd
moder
sever
asthma
likewis
treatment
variou
refractori
lung
diseas
also
depend
system
corticosteroid
therapi
mani
patient
also
suffer
variou
side
effect
system
corticosteroid
use
weight
gain
uncontrol
hyperglycemia
treatment
lung
diseas
use
cellspecif
target
well
rnai
techniqu
repres
novel
strategi
could
possibl
provid
new
opportun
nanomedicin
pulmonari
applic
sirna
vivo
condit
frequent
studi
often
result
clinic
trial
find
recent
clinic
studi
pulmonari
rnai
therapeut
discuss
sinc
discoveri
rnai
therapeut
potenti
sirna
rapidli
recogn
first
human
clinic
trial
rnaibas
therapi
initi
treatment
agerel
macular
degener
sirna
target
vegfreceptor
deliv
intravitr
mani
studi
conduct
past
year
involv
deliveri
sirna
lung
treatment
variou
lung
diseas
deliveri
lung
import
move
sirna
technolog
clinic
number
sirnabas
therapi
evalu
clinic
trial
treatment
differ
condit
includ
lung
diseas
asthma
rsv
infect
tabl
summari
clinic
trial
sirnabas
therapeut
sirna
show
potenti
treatment
variou
pulmonari
viral
infect
report
sirnabas
therapeut
also
use
treatment
influenza
parainfluenza
viru
sever
acut
respiratori
syndrom
sar
rsv
rsv
promis
therapeut
target
sirna
rsv
common
caus
seriou
respiratori
infect
infant
children
also
produc
signific
morbid
mortal
adult
immunocompromis
elderli
popul
rsv
vaccin
avail
approv
antivir
therapi
rsv
undesir
pediatr
patient
due
potenti
teratogen
limit
effect
thu
safe
efficaci
rsv
therapi
long
await
pediatr
adult
patient
rnaibas
therapi
shown
promis
effect
murin
model
rsv
infect
sirna
direct
mrna
encod
nprotein
rsv
exhibit
specif
vitro
vivo
antirsv
activ
deliv
without
deliveri
vector
nasal
spray
target
upper
respiratori
tract
instead
lower
lung
area
undergon
complet
phase
intranas
inhal
studi
healthi
adult
found
gener
well
toler
addit
evalu
random
doubleblind
placebocontrol
phase
ii
trial
lung
transplant
patient
rsv
respiratori
tract
infect
administr
rsv
infect
lung
transplant
patient
safe
well
toler
associ
statist
signific
improv
symptom
base
result
larger
multin
random
doubleblind
phase
iib
trial
initi
lung
transplant
patient
confirm
extend
find
cancer
major
target
rnaibas
therapi
oncogen
mutat
tumor
suppressor
gene
sever
gene
contribut
tumor
progress
potenti
import
target
gene
silenc
rnai
lung
cancer
one
frequent
tumor
worldwid
regard
incid
rate
mortal
patient
lung
cancer
commonli
diagnos
advanc
stage
diseas
limit
therapeut
option
although
knowledg
regard
genet
molecular
basi
lung
cancer
regularli
increas
median
surviv
rate
individu
advanc
lung
cancer
still
poor
rnaibas
therapi
attract
strategi
develop
effect
anticanc
therapi
reduc
treatmentrel
toxic
major
advantag
rnai
therapeut
cancer
might
simultan
target
multipl
gene
belong
differ
cellular
pathway
involv
tumor
progress
simultan
inhibit
sever
gene
would
also
minim
risk
drug
resist
normal
encount
small
moleculebas
therapi
involv
sirna
mirna
alreadi
signific
improv
sirna
primari
metastat
lung
cancer
treatment
target
oncogen
wilm
tumor
overexpress
gene
insulinlik
growth
factor
receptor
studi
success
shown
efficaci
rnaibas
therapi
intrapulmonari
administr
sirna
nonvir
vector
although
strategi
minim
offtarget
nonspecif
immun
stimulatori
effect
must
devis
data
suggest
silenc
target
gene
sirna
attract
strategi
prevent
treatment
primari
metastat
lung
cancer
current
clinic
trial
progress
estim
safeti
efficaci
sirnabas
drug
cancer
treatment
sirnalipoplex
target
protein
kinas
prevent
lung
metastasi
phase
trial
variou
cancer
model
downstream
effector
phosphoinositid
signal
pathway
regul
divers
cellular
respons
includ
develop
growth
surviv
recent
also
consid
suitabl
therapeut
target
modul
tumor
angiogenesi
loss
function
analysi
cultur
primari
endotheli
cell
show
essenti
role
endotheli
tube
format
migrat
consid
potenti
sirna
prevent
lung
metastasi
might
suitabl
prevent
hematogen
metastasi
combin
convent
cancer
therapi
inflammatori
lung
diseas
also
call
copd
includ
wide
rang
lung
ailment
relat
diseas
includ
asthma
pulmonari
fibrosi
chronic
bronchiti
influenc
combin
environment
genet
epigenet
compon
copd
chronic
inflammatori
diseas
airway
diseas
hallmark
airflow
fulli
revers
system
local
airway
inflamm
implic
pathogenesi
copd
copd
mainli
associ
tobacco
smoke
recent
studi
investig
pathophysiolog
emphysema
demonstr
cigarett
smoke
caus
cell
enter
cellular
senesc
smoke
might
caus
cell
senesc
due
dna
damag
increas
cell
turnov
turn
lead
acceler
telomer
shorten
late
lot
studi
investig
role
cellular
senesc
develop
progress
copd
although
sever
medic
class
includ
inhal
corticosteroid
use
copd
treatment
none
medic
shown
significantli
improv
longterm
lung
function
progress
diseas
current
intervent
shown
improv
mortal
copd
cessat
smoke
deliveri
supplement
oxygen
hypoxemia
present
mani
peopl
develop
copd
caus
condit
complic
thoroughli
understood
one
key
factor
genet
suscept
studi
shown
larg
genet
contribut
variabl
pulmonari
function
copd
polymorph
multipl
gene
report
associ
copd
transcript
factor
eg
nuclear
factorkappa
b
extracellular
matrix
eg
matrix
cytokin
eg
tumor
necrosi
factor
tnf
chemokin
eg
interleukin
il
receptor
chemokin
receptor
ccr
apoptosi
eg
vascular
endotheli
growth
factor
vegf
mani
identifi
possibl
target
therapeut
intervent
use
molecul
inhibitor
antagonist
although
sever
new
treatment
target
inflammatori
process
clinic
develop
inhibitor
ikappab
kinas
complex
inhibitor
clinic
trial
sirna
never
perform
copd
delay
drug
develop
copd
might
due
rel
recent
emerg
research
address
molecular
basi
copd
furthermor
research
need
understand
essenti
molecular
mechan
pathogenesi
copd
develop
monitor
techniqu
support
develop
rnai
therapi
current
avail
treatment
reduc
progress
copd
suppress
inflamm
small
airway
lung
parenchyma
rnaibas
approach
key
molecul
also
potenti
implic
treatment
copd
asthma
also
chronic
inflammatori
diseas
airway
character
variabl
recur
symptom
revers
airflow
obstruct
world
health
organ
estim
million
peopl
current
affect
year
anoth
million
affect
diseas
inhal
corticosteroid
effect
mild
asthma
improv
symptom
decreas
exacerb
howev
moder
sever
asthma
inhal
corticosteroid
import
therapeut
limit
although
corticosteroid
remain
import
therapeut
intervent
inflammatori
lung
diseas
use
alway
complet
effect
associ
side
effect
due
limit
clear
need
new
type
medic
treat
improv
prognosi
moder
sever
asthma
mani
target
gene
identifi
particip
pathogenesi
asthma
promis
target
includ
gene
code
cytokin
cytokin
chemokin
receptor
receptor
tyrosin
kinas
spleen
tyrosin
kinas
syk
lckyesrel
novel
tyrosin
kinas
lyn
well
transcript
factor
signal
transduc
activ
transcript
involv
asthma
gene
assess
sirna
target
treatment
asthma
preclin
model
report
current
clinic
trial
asthma
excellair
tm
zabecor
bala
cynwyd
pa
usa
sirna
target
syk
use
kinas
involv
signal
b
cell
receptor
key
regul
downstream
signal
cascad
ultim
lead
activ
sever
proinflammatori
transcript
factor
report
antisens
oligonucleotid
administ
aerosol
potent
decreas
syk
express
mediat
releas
alveolar
macrophag
sykdepend
pulmonari
inflamm
moreov
inhibit
inflammatori
mediat
shown
studi
use
sirna
target
syk
airway
epitheli
cell
follow
success
result
compani
phase
clinic
trial
phase
ii
trial
asthma
drug
candid
excellair
tm
alreadi
initi
current
treatment
asthma
inflammatori
condit
inhibitor
leukotrien
inhibitor
inhibit
one
mediat
inflamm
contrast
sirna
target
syk
seek
inhibit
initi
signal
step
inflamm
therebi
prevent
releas
multipl
inflammatori
mediat
overal
recent
progress
sirna
lung
also
improv
therapeut
feasibl
rnai
inflammatori
lung
diseas
rapid
progress
put
sirnabas
therapeut
fast
track
clinic
mirna
small
endogen
noncod
rna
regul
gene
express
repress
translat
promot
degrad
target
mrna
mirna
regul
gene
express
bind
untransl
region
utr
target
mrna
mediat
mrna
degrad
translat
inhibit
human
genom
transcript
approxim
mrna
estim
target
mirna
accord
function
mirna
play
import
role
cellular
process
develop
prolifer
apoptosi
pulmonari
patholog
grow
number
mirna
shown
involv
differ
lung
diseas
evid
make
mirna
promis
technolog
current
futur
therapeut
develop
discuss
role
mirna
variou
lung
diseas
well
possibl
futur
discoveri
clinic
applic
tabl
show
summari
mirna
therapeut
develop
point
mirnabas
therapi
alreadi
enter
phase
ii
clinic
trial
evid
upregul
downregul
mirna
critic
lung
homeostasi
thu
may
contribut
develop
patholog
pulmonari
condit
mani
studi
focus
role
mirna
inflammatori
lung
diseas
copd
pulmonari
fibrosi
asthma
tabl
pathogenesi
copd
attribut
chronic
inflamm
airway
also
system
inflamm
cigarett
smoke
main
risk
factor
develop
copd
smoke
shown
caus
biolog
chang
gene
express
lung
report
smokingrel
mirna
howev
report
focu
mirna
relat
pathogenesi
diseas
system
inflammatori
compon
recent
studi
pulmonari
fibroblast
copd
patient
present
less
express
stimul
proinflammatori
cytokin
compar
noncopd
subject
similar
smoke
histori
downregul
result
prolong
mrna
halflif
thu
increas
prostaglandin
fibroblast
copd
subject
moreov
ezzi
et
al
research
differ
mirna
profil
express
lung
smoker
without
copd
conclud
affect
mirna
subject
copd
yet
copd
complex
multicompon
heterogen
disord
number
differ
patholog
process
subgroup
characterist
natur
histori
better
understand
complex
diseas
potenti
clinic
relev
identifi
mirna
need
pulmonari
fibrosi
caus
identifi
irrit
lung
mani
case
caus
unknown
therapeut
possibl
limit
cigarett
smoke
one
recogn
risk
factor
develop
pulmonari
fibrosi
disord
mainli
accompani
increas
express
key
fibrot
mediat
transform
growth
factor
cytokin
produc
lesion
activ
fibrosi
recent
report
mirna
may
play
import
regulatori
role
pulmonari
fibrot
chang
lung
downregul
idiopath
pulmonari
fibrosi
ipf
result
increas
collagen
deposit
alveolar
septal
thicken
addit
liu
et
al
report
oncogen
found
upregul
ipf
patient
murin
lung
bleomycininduc
fibrosi
although
mirna
may
potenti
therapeut
target
express
relat
regul
factor
necessari
suffici
patholog
fibrosi
lung
pulmonari
fibrosi
also
complic
ill
mani
differ
caus
focu
role
mirna
asthma
recent
increas
asthma
inflammatori
diseas
airway
character
abnorm
respons
type
lymphocyt
inhal
allergen
differ
asthmat
mous
model
observ
increas
express
lung
report
might
contribut
understand
inflammatori
mechan
airway
inhibit
favor
lymphocyt
respons
tolllik
receptor
induc
lymphocyt
induc
high
express
select
blockad
suppress
asthmat
phenotyp
addit
airway
remodel
characterist
featur
asthma
import
function
implic
rodriguez
et
al
shown
relat
develop
inflammatori
infiltr
lung
airway
remodel
thu
studi
present
function
connect
mirna
express
asthma
pathogenesi
suggest
target
mirna
airway
may
lead
antiinflammatori
treatment
allerg
asthma
despit
evid
experiment
model
express
profil
mirna
airway
biopsi
patient
mild
asthma
treatment
inhal
corticosteroid
healthi
volunt
reveal
differ
mirna
express
investig
role
mirna
relat
asthma
pathogenesi
requir
although
basic
evid
mirna
biolog
still
provid
new
insight
applic
mirnabas
therapi
inflammatori
lung
diseas
less
advanc
lung
cancer
one
reason
could
diseas
heterogen
caus
effect
mani
environment
air
pollut
includ
smoke
volatil
organ
compound
presenc
sever
risk
factor
make
understand
pathogenesi
inflammatori
lung
diseas
complic
understand
role
mirna
play
modul
gene
express
lead
sustain
pathogenesi
lung
diseas
import
develop
new
therapi
focu
prevent
diseas
progress
symptom
relief
given
signific
role
mirna
play
multipl
pathway
lung
carcinogenesi
increas
effort
dedic
research
develop
mirnabas
therapi
includ
restor
function
tumor
suppress
mirna
inhibit
oncogen
mirna
develop
mirnabas
therapi
lung
cancer
grow
prosper
help
new
rnai
technolog
compar
sirnabas
therapi
alreadi
clinic
trial
mirna
less
toxic
potenti
target
multipl
gene
difficulti
associ
mirna
deliveri
mainli
equal
sirna
critic
problem
develop
therapi
effect
deliveri
target
site
potenc
therapi
elimin
offtarget
effect
two
strategi
therapeut
applic
mirna
lung
cancer
one
strategi
mirna
replac
therapi
involv
reintroduct
tumor
suppressor
mirna
mimic
restor
loss
function
mirna
mimic
synthet
rna
duplex
design
mimic
endogen
function
mirna
chemic
modif
stabil
cellular
uptak
concept
mirna
replac
therapi
exemplifi
mirna
tumorsuppressor
mirna
nonsmallcel
lung
cancer
invers
correl
express
ra
oncoprotein
key
cancer
gene
intranas
administr
mimic
mous
model
lung
cancer
significantli
reduc
tumor
growth
suggest
mirna
replac
therapi
inde
promis
anoth
mirna
show
valu
mirna
replac
provid
local
andor
system
deliveri
synthet
mimic
led
accumul
tumor
tissu
inhibit
lung
tumor
growth
late
ling
et
al
also
show
tumor
suppressor
exhibit
antilung
cancer
activ
posttranscript
regul
thu
therapeut
mirna
mimic
power
potenti
attack
multipl
gene
relev
sever
diseas
howev
necessari
pay
attent
potenti
toxic
normal
tissu
condit
therapeut
deliveri
mirna
mimic
lead
accumul
exogen
mirna
normal
cell
although
assumpt
well
found
still
insuffici
evid
toxic
caus
mirna
mimic
inde
sever
vivo
studi
fail
reveal
side
effect
caus
mirna
mimic
suggest
deliveri
mirna
mimic
normal
tissu
well
toler
import
research
mirna
mimicinduc
effect
normal
cell
care
assess
toxic
use
clinic
practic
second
strategi
direct
toward
gain
function
aim
inhibit
oncomir
use
antimirna
chemic
modif
lock
nucleic
acid
lna
would
increas
oligo
stabil
nucleas
antisens
oligonucleotid
contain
modif
term
antagomir
lnaantimir
oligonucleotid
sequenc
complementari
endogen
mirna
inhibit
specif
mirna
function
lnaantimir
shown
effect
silenc
nonhuman
primat
find
support
potenti
compound
new
class
therapeut
moreov
also
report
deliv
lung
tumor
xenograft
mice
led
inhibit
tumor
growth
rel
studi
mirna
mimic
studi
antisens
oligonucleotid
shown
effect
evid
nake
oligonucleotid
illustr
potenti
chemic
modif
oligonucleotid
improv
stabil
resist
rnase
pharmacolog
properti
therefor
inhibit
mirna
function
chemic
modifi
antimir
oligonucleotid
becom
import
wide
use
approach
recent
data
first
phase
ii
studi
patient
chronic
hcv
infect
treat
lnamodifi
show
compound
well
toler
provid
continu
viral
suppress
increas
number
studi
examin
therapeut
potenti
mirna
recent
evid
role
mirna
determin
drug
resist
emerg
cytotox
molecular
target
drug
wide
use
treatment
advanc
lung
cancer
unfortun
mani
case
still
refractori
chemotherapi
situat
combin
mirna
mimic
antimir
chemotherapi
may
potenti
efficaci
cancer
treatment
futur
addit
mirna
relat
cancer
stem
cell
may
significantli
broaden
field
mirnabas
therapi
suggest
mirna
potenti
tool
kill
cancer
cell
associ
therapi
resist
recurr
metastasi
henc
main
challeng
success
deliveri
chemic
modif
therapeut
mirna
target
tissu
without
harm
normal
tissu
rnaibas
approach
provid
promis
therapeut
modal
treatment
variou
lung
diseas
one
greatest
challeng
rnaibas
therapi
continu
deliveri
method
therapeut
sirna
mirna
target
cell
pulmonari
deliveri
applic
attract
sinc
tend
noninvas
local
restrict
administ
patient
realist
therapeut
intervent
aerosol
enhanc
drug
deliveri
site
action
decreas
system
exposur
patient
therapi
therebi
reduc
offtarget
effect
advanc
pulmonari
sirna
deliveri
clinic
illustr
rnaibas
therapi
hold
central
place
futur
treatment
lung
diseas
hand
mirna
opportun
target
multipl
gene
finetun
manner
mirnabas
therapi
provid
attract
antitumor
antiinflammatori
approach
variou
lung
diseas
particular
antimirna
therapi
chemic
modifi
antimir
oligonucleotid
becom
potenti
therapi
lung
diseas
oligonucleotid
success
deliv
without
deliveri
vector
increas
evid
indic
mirna
fulfil
caus
role
varieti
lung
diseas
prompt
investig
potenti
therapeut
target
understand
detail
mechan
rnaibas
therapi
investig
effect
deliveri
method
requir
futur
develop
novel
approach
could
open
new
avenu
variou
lung
diseas
improv
clinic
outcom
patient
